Antitrust & Trade Reg.
Jan. 24, 2024
Class counsel get $75M in fees for HIV drug antitrust case
Plaintiffs lawyers argued the fee was warranted because there was no companion criminal case for them to utilize or leverage.
Class counsel in an antitrust lawsuit against Gilead Sciences Inc. will receive $75 million in fees after the parties resolved allegations last fall that the company conspired to delay generic HIV drugs from entering the market.
Attorneys for the direct purchasers, led by Roberts Law Firm PA in Dallas and NastLaw LLC in Philadelphia, will get an additional $2.9 million to...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In